@MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce
> St. Jude Medical's ($STJ) stock is down about 24% from this time last year, but promising devices on the horizon could pay off big for the company, Barron's reports, and its shares could go up by 33% this year. Analysis
> On the heels of recalling its Roticulator line of staplers, Covidien ($COV) is launching the Endo GIA Radial Reload, a stapler designed for colorectal surgeries. Release
> A NeuroSigma-funded clinical trial at UCLA has generated promising initial results using external trigeminal nerve stimulation to treat post-traumatic stress disorder and major depression, along with drug therapy. Release
> Critical Diagnostics has hired Richard Hughes as its vice president of business development for Europe. He's a veteran industry executive who has worked for companies including Alere and British Biocell. Release
> Insight Genetics, a molecular diagnostics company, has licensed a lung cancer test to Chinese competitor, Kindstar Globalgene (Beijing) Technology. The deal is the first stem in a partnership designed to expand the availability of molecular diagnostics tests for cancer in China. Release
Biotech News
@FierceBiotech: Forest Labs nabs rights to anti-MRSA antibiotic from Nabriva for $25M. Release | Follow @FierceBiotech
@JohnCFierce: Now this you hardly ever see: BMS CEO throws down the gauntlet on Gilead, demands combo hep c study. Check it out. News | Follow @JohnCFierce
@RyanMFierce: How many times did Marina change its name during lackluster run? I count at least 2 changes. | Follow @RyanMFierce
> Genzyme/Sanofi's oral MS drug Aubagio beats placebo in PhIII. More
> New chairman ramps up CEO search at struggling AZ. Article
> Marina Biotech hits a funding wall, shuts down RNAi ops. Story
> Bristol CEO says Gilead holding out on hep C tie-up. News
Pharma News
@FiercePharma: PhRMA emails show behind-the-scenes dickering on industry's healthcare reform deal--WSJ. More | Follow @FiercePharma
> South Koreans eating up generic Viagra. Story
> Judge blocks run at Human Genome's 'poison pill' defense. More
> New AstraZeneca chairman looks for CEO. Article
> Takeda recruit refocuses marketing, R&D on emerging markets. More
> And Finally... Researchers in Switzerland were able to use electrical and chemical stimulation to help rats paralyzed by spinal cord injury learn to move their hind legs again, while wearing a rehabilitation device, MIT's Technology Review reports. Story